


**Listing of Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1. (Original) A compound having the formula



the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

R<sup>1</sup> represents hydrogen, Ar<sup>1</sup>, C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with morpholinyl or pyridinyl;

R<sup>2</sup> represents hydrogen, phenyl, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl or C<sub>1-4</sub>alkyl substituted with hydroxy, phenyl or -oxy-halophenyl;

R<sup>3</sup> represents hydrogen, phenyl, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl or C<sub>1-4</sub>alkyl substituted with hydroxy, phenyl or -oxy-halophenyl; or

R<sup>2</sup> and R<sup>3</sup> taken together with the carbon atom to which they are attached form a C<sub>3-8</sub>cycloalkyl or Het<sup>1</sup> wherein said C<sub>3-8</sub>cycloalkyl or Het<sup>1</sup> each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C<sub>1-4</sub>alkyloxycarbonyl, -C<sub>1-4</sub>alkyl-Ar<sup>3</sup>, C<sub>1-4</sub>alkylsulfonyl, aminosulfonyl, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl or -C(=NH)-NH<sub>2</sub>;

R<sup>4</sup> represents halo, nitro, hydroxy or C<sub>1-4</sub>alkyloxy;

R<sup>5</sup> represents formyl, hydroxy, cyano, phenyl, -O-Ar<sup>2</sup>, NR<sup>6</sup>R<sup>7</sup>, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkyloxycarbonyl, -O-(mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl), Het<sup>2</sup>, -SO<sub>2</sub>-Het<sup>6</sup>, C<sub>2-6</sub>alkenyl optionally substituted with phenyl,

C<sub>1-4</sub>alkyl substituted with one or where possible more substituent being selected from hydroxy, halo, Het<sup>3</sup>, NR<sup>6</sup>R<sup>7</sup> or formyl,

C<sub>1-4</sub>alkyloxy substituted with one or where possible more substituents being selected from halo, amino, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, aminosulfonyl, Het<sup>4</sup>, NR<sup>8</sup>R<sup>9</sup> or -C(=O)-Het<sup>4</sup>;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl,

C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, Het<sup>5</sup> or C<sub>1-4</sub>alkyl substituted with one or where possible more substituents being selected from hydroxy, Het<sup>5</sup>, C<sub>1-4</sub>alkyloxycarbonyl, or C<sub>1-4</sub>alkylsulfonyl;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, Het<sup>7</sup>, mono- or di(C<sub>1-4</sub>alkyl)aminosulphonyl or aminosulphonyl;

Het<sup>1</sup> represents piperidinyl or dihydroindenyl;


Het<sup>2</sup> represents a heterocycle selected from piperidinyl, morpholinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C<sub>1-4</sub>alkyloxycarbonyl;

Het<sup>3</sup> represents a heterocycle selected from morpholinyl, pyrrolidinyl, pyrrolyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, hydroxyC<sub>1-4</sub>alkyl, aminosulfonyl, NR<sup>10</sup>R<sup>11</sup>, imidazolyl, tetrahydropyrimidinyl, amino, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, hydroxyC<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy;

R<sup>10</sup> and R<sup>11</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl,

C<sub>1-4</sub>alkyloxycarbonyl, aminosulfonyl, or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;

Het<sup>4</sup> represents a heterocycle selected from morpholinyl, piperidinyl, imidazolyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, aminosulfonyl or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl or Het<sup>4</sup> represents a monovalent radical represented by formula (i);



Het<sup>5</sup> represents a heterocycle selected from pyridinyl, pyrimidinyl, pyrrolidinyl, or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, aminosulfonyl, C<sub>1-4</sub>alkylaminosulfonyl or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;

Het<sup>6</sup> represents morpholinyl;

Het<sup>7</sup> represents pyridinyl, piperidinyl, piperazinyl or pyrimidinyl optionally substituted with C<sub>1-4</sub>alkylphenyl, C<sub>1-4</sub>alkyloxycarbonyl aminosulfonyl, or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;

Ar<sup>1</sup> represents an aryl substituent selected from phenyl or naphthalenyl wherein said aryl substituents each independently may optionally be substituted with one, or where possibly two or three substituents each independently selected from nitro or C<sub>1-4</sub>alkyloxycarbonyl;

Ar<sup>2</sup> represents phenyl optionally substituted with one or where possible two or three substituents each independently selected from the group consisting of halo and nitro;

Ar<sup>3</sup> represents an aryl substituent selected from the group consisting of phenyl,

2. (Original) A compound according to claim 1 wherein;

R<sup>1</sup> represents Ar<sup>1</sup>, C<sub>1-4</sub>alkyl preferably methyl, or C<sub>1-4</sub>alkyl substituted with morpholinyl;

R<sup>2</sup> represents hydrogen or C<sub>1-4</sub>alkyl;

R<sup>3</sup> represents hydrogen or C<sub>1-4</sub>alkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together with the carbon atom to which they are attached form a C<sub>3-8</sub>cycloalkyl or Het<sup>1</sup> wherein said C<sub>3-8</sub>cycloalkyl or Het<sup>1</sup> each independently may optionally be substituted with C<sub>1-4</sub>alkyloxycarbonyl;

R<sup>4</sup> represents halo preferably chloro or R<sup>4</sup> represents C<sub>1-4</sub>alkyloxy preferably methoxy;

R<sup>5</sup> represents C<sub>1-4</sub>alkyloxycarbonyl, -O-(mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl), C<sub>1-4</sub>alkyl substituted with one or where possible more substituent being selected from Het<sup>3</sup> or NR<sup>6</sup>R<sup>7</sup>,

C<sub>1-4</sub>alkyloxy substituted with one or where possible more substituents being selected from amino, Het<sup>4</sup> or NR<sup>8</sup>R<sup>9</sup>;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl,

C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, Het<sup>5</sup> or C<sub>1-4</sub>alkyl substituted with one or where possible more substituents being selected from hydroxy or Het<sup>5</sup>;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, Het<sup>7</sup> or mono- or di(C<sub>1-4</sub>alkyl)aminosulphonyl;  
Het<sup>1</sup> represents piperidinyl;  
Het<sup>3</sup> represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, aminosulfonyl, amino, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, hydroxyC<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy;  
Het<sup>5</sup> represents pyridinyl optionally substituted with mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;  
Het<sup>7</sup> represents piperidinyl optionally substituted with C<sub>1-4</sub>alkylphenyl, C<sub>1-4</sub>alkyloxycarbonyl, or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;  
Ar<sup>1</sup> represents an aryl substituent selected from phenyl or naphthalenyl;

3. (Original) A compound according to claim 1 wherein;


R<sup>1</sup> represents C<sub>1-4</sub>alkyl preferably methyl;  
R<sup>2</sup> represents C<sub>1-4</sub>alkyl preferably methyl;  
R<sup>3</sup> represents C<sub>1-4</sub>alkyl preferably methyl; or  
R<sup>2</sup> and R<sup>3</sup> taken together with the carbon atom to which they are attached form a C<sub>3-8</sub>cycloalkyl preferably cyclopentyl or Het<sup>1</sup> preferably piperidinyl wherein said C<sub>3-8</sub>cycloalkyl or Het<sup>1</sup> each independently may optionally be substituted with C<sub>1-4</sub>alkyloxycarbonyl preferably t-butoxycarbonyl;  
R<sup>4</sup> represents halo or C<sub>1-4</sub>alkyloxy;  
R<sup>5</sup> represents C<sub>1-4</sub>alkyloxycarbonyl, -O-(mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl), C<sub>1-4</sub>alkyl substituted with one or where possible more substituent being selected from Het<sup>3</sup> or NR<sup>6</sup>R<sup>7</sup>, C<sub>1-4</sub>alkyloxy substituted with one or where possible more substituents being selected from amino, Het<sup>4</sup> or NR<sup>8</sup>R<sup>9</sup>;  
R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, -Het<sup>5</sup> or C<sub>1-4</sub>alkyl substituted with one or where possible more substituents being selected from hydroxy, or Het<sup>5</sup>;  
R<sup>8</sup> and R<sup>9</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, -Het<sup>7</sup> or mono- or di(C<sub>1-4</sub>alkyl)aminosulphonyl;  
Het<sup>3</sup> represents a heterocycle selected from piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently

selected from hydroxy, aminosulfonyl, amino, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, hydroxyC<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy;  
Het<sup>4</sup> represents a heterocycle selected from morpholinyl, piperidinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;  
Het<sup>5</sup> represents a heterocycle selected from pyridinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, or mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl;  
Het<sup>7</sup> represents piperidinyl.


4. (Currently Amended) A compound as claimed claim 1, ~~in any one of claims 1 to 3~~ wherein R<sup>2</sup> and R<sup>3</sup> taken together with the carbon atom to which they are attached form a C<sub>3-8</sub>cycloalkyl, preferably cyclopentyl.
5. (Original) A compound according to claim 1 wherein R<sup>5</sup> represents formyl, hydroxy, cyano, phenyl, -O-Ar<sup>2</sup>, NR<sup>6</sup>R<sup>7</sup>, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkyloxycarbonyl, -O-(mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl), Het<sup>2</sup>, -SO<sub>2</sub>-Het<sup>6</sup>, C<sub>2-6</sub>alkenyl optionally substituted with phenyl, C<sub>1-4</sub>alkyl substituted with one or where possible more substituent being selected from hydroxy, halo, Het<sup>3</sup>, NR<sup>6</sup>R<sup>7</sup> or formyl, or C<sub>1-4</sub>alkyloxy substituted with one or where possible more substituents being selected from halo, amino, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, aminosulfonyl, Het<sup>4</sup>, NR<sup>8</sup>R<sup>9</sup> or -C(=O)-Het<sup>4</sup>;
6. (Currently Amended) A compound according to claim 1, ~~claims 1 or 5~~ provided that when R<sup>5</sup> represents NR<sup>6</sup>R<sup>7</sup>, either R<sup>6</sup> or R<sup>7</sup> represents C<sub>1-4</sub>alkylsulfonyl or C<sub>1-4</sub>alkylcarbonyl, preferably methylsulfonyl or methylcarbonyl.
7. (Currently Amended) A compound as claimed in claim 1, ~~any one of claims 1 to 5~~ provided that when R<sup>5</sup> represents a C<sub>1-4</sub>alkyloxy substituted Het<sup>4</sup>, said Het<sup>4</sup> being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C<sub>1-4</sub>alkyl substituent, preferably methyl, more preferably with the methyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent, or Het<sup>4</sup> consists of piperazinyl substituted with one mono- or

di(C<sub>1-4</sub>alkyl)aminosulfonyl substituent, preferably dimethylaminosulfonyl, more preferably with the dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent.

8. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective kinase inhibitory amount of a compound as described in claim 1 ~~any one of the claims 1 to 7~~.
9. (Currently Amended) A process of preparing a pharmaceutical composition as defined in claim 8, ~~characterized in that,~~ comprising a pharmaceutically acceptable carrier is intimately mixed with an effective kinase inhibitory amount of a compound as described in claim 1 ~~any one of claims 1 to 7~~.
10. (Currently Cancelled)
11. (Currently Cancelled)
12. (Currently Amended) A process of preparing a compound as described in claim 1, comprising ~~characterized by~~
- i) reacting a primary amine of formula (V) with an aldehyde of formula (VI) in a condensation reaction using ethanol as a suitable solvent;



- ii) followed by a nitrosative cyclisation of the thus obtained Schiff's bases of formula (II) with NaNO<sub>2</sub> in acetic acid, and refluxing the nitroso intermediates of formula (III) in a suitable solvent such as acetic anhydride or ethanol further comprising dithiothreitol (DTT);



13. (New) A compound as claimed claim 2, wherein  $\text{R}^2$  and  $\text{R}^3$  taken together with the carbon atom to which they are attached form a  $\text{C}_{3-8}$ cycloalkyl, preferably cyclopentyl.
14. (New) A compound as claimed claim 3, wherein  $\text{R}^2$  and  $\text{R}^3$  taken together with the carbon atom to which they are attached form a  $\text{C}_{3-8}$ cycloalkyl, preferably cyclopentyl.
15. (New) A compound according to claim 2, provided that when  $\text{R}^5$  represents  $\text{NR}^6\text{R}^7$ , either  $\text{R}^6$  or  $\text{R}^7$  represents  $\text{C}_{1-4}$ alkylsulfonyl or  $\text{C}_{1-4}$ alkylcarbonyl, preferably methylsulfonyl or methylcarbonyl.
16. (New) A compound according to claim 3, provided that when  $\text{R}^5$  represents  $\text{NR}^6\text{R}^7$ , either  $\text{R}^6$  or  $\text{R}^7$  represents  $\text{C}_{1-4}$ alkylsulfonyl or  $\text{C}_{1-4}$ alkylcarbonyl, preferably methylsulfonyl or methylcarbonyl.
17. (New) A compound according to claim 4, provided that when  $\text{R}^5$  represents  $\text{NR}^6\text{R}^7$ , either  $\text{R}^6$  or  $\text{R}^7$  represents  $\text{C}_{1-4}$ alkylsulfonyl or  $\text{C}_{1-4}$ alkylcarbonyl, preferably methylsulfonyl or methylcarbonyl.
18. (New) A compound according to claim 5, provided that when  $\text{R}^5$  represents  $\text{NR}^6\text{R}^7$ , either  $\text{R}^6$  or  $\text{R}^7$  represents  $\text{C}_{1-4}$ alkylsulfonyl or  $\text{C}_{1-4}$ alkylcarbonyl, preferably methylsulfonyl or methylcarbonyl.
19. (New) A compound as claimed in claim 2, provided that when  $\text{R}^5$  represents a  $\text{C}_{1-4}$ alkyloxy substituted  $\text{Het}^4$ , said  $\text{Het}^4$  being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one  $\text{C}_{1-4}$ alkyl substituent, preferably methyl, more preferably with the methyl in the para position relative to the carbon atom bearing the  $\text{R}^5$  substituent, or  $\text{Het}^4$  consists of

piperazinyl substituted with one mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl substituent, preferably dimethylaminosulfonyl, more preferably with the dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent.

20. (New) A compound as claimed in claim 2, provided that when R<sup>5</sup> represents a C<sub>1-4</sub>alkyloxy substituted Het<sup>4</sup>, said Het<sup>4</sup> being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C<sub>1-4</sub>alkyl substituent, preferably methyl, more preferably with the methyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent, or Het<sup>4</sup> consists of piperazinyl substituted with one mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl substituent, preferably dimethylaminosulfonyl, more preferably with the dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent.
21. (New) A compound as claimed in claim 3, provided that when R<sup>5</sup> represents a C<sub>1-4</sub>alkyloxy substituted Het<sup>4</sup>, said Het<sup>4</sup> being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C<sub>1-4</sub>alkyl substituent, preferably methyl, more preferably with the methyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent, or Het<sup>4</sup> consists of piperazinyl substituted with one mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl substituent, preferably dimethylaminosulfonyl, more preferably with the dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent.
22. (New) A compound as claimed in claim 4, provided that when R<sup>5</sup> represents a C<sub>1-4</sub>alkyloxy substituted Het<sup>4</sup>, said Het<sup>4</sup> being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C<sub>1-4</sub>alkyl substituent, preferably methyl, more preferably with the methyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent, or Het<sup>4</sup> consists of piperazinyl substituted with one mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl substituent, preferably dimethylaminosulfonyl, more preferably with the dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent.

23. (New) A compound as claimed in claim 5, provided that when R<sup>5</sup> represents a C<sub>1-4</sub>alkyloxy substituted Het<sup>4</sup>, said Het<sup>4</sup> being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C<sub>1-4</sub>alkyl substituent, preferably methyl, more preferably with the methyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent, or Het<sup>4</sup> consists of piperazinyl substituted with one mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl substituent, preferably dimethylaminosulfonyl, more preferably with the dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R<sup>5</sup> substituent.